Voyager Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire•05/11/2026•16:01 ET
0
Key Highlights
- ➤Cash position $132.1 million, funding planned operations into Q2 2028
- ➤VY7523 tau PET imaging efficacy data remains expected in Q4 2026
- ➤VY1706 first patient dosing expected in the next few months, pending enrollment
- ➤Third-quarter collaboration revenue fell to $4.0 million from $13.4 million
- ➤Third-quarter net loss narrowed to $24.7 million from $27.9 million
Expert Statements
Alfred W. Sandrock, Jr., Chief Executive Officer of Voyager Therapeutics
“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months”
Alfred W. Sandrock, Jr., Chief Executive Officer of Voyager Therapeutics
“During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028. This strengthens our position as we approach key upcoming milestones.”
- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -
- Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter the clinic in the coming months -
Get started
Create a free account to read the full story.